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ABSTRACT 
Martin, Jamee Covington. M.S. The University of Memphis. 12/2011.  Chemotherapy 
Induced Mucositis: A Novel Porcine Model. Major Professor: Dr. Randal K. Buddington 
 
Chemotherapy-induce mucositis (CIM) is a dose-limiting side effect of cancer 
therapy with concurrent nausea, vomiting, diarrhea, lethargy, and decreased food 
consumption. Of the pediatric population approximately 40% of patients receiving 
standard dose and 100% of patients receiving high dose chemotherapy are afflicted. 
Although scientific advancements have improved pediatric cancer survival rates, 
occurrence of mucositis decreases quality of life, increases treatment interruptions or 
even delays therapy, and often reduces the dose. Currently, there are no relevant animal 
models studying the entire gastrointestinal tract (GIT). Based on these findings, we 
decided to develop a novel porcine model for CIM. Examination of the entire GIT with 
coinciding clinical symptom, lead to the findings of CIM with the administration of 
single dose Doxorubicin, HCL (75mg/m2). A novel porcine CIM model will permit for an 
improved understanding of the disease process with regard to chemotherapy dosing and 
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CHAPTER I 
INTRODUCTION  
 Innovative cancer therapies utilize prognostic models for determining the 
anatomical characteristics of various cancers for proper diagnosis. Cancer is 
characterized by the growth and spread of abnormal cells through the impact of external 
and internal risk factors. The type, location, severity of growth, metastasis, and size of the 
cancer allows for differentiation and therefore choice of therapy 1. 
 The frontline therapy for the treatment of cancer is the administration of 
chemotherapeutic agents.  Anthracyclines, a class of chemotherapeutic agents, are anti-
tumor antibiotics that impede DNA replication enzymes. Due to the mechanism of action 
of anthracyclines, there is a profound influence on normal cells that divide rapidly, such 
as the stem cells in the mucosa of the gastrointestinal tract (GI).   
Post-chemotherapy administration the GI mucosa is damaged, resulting in a 
painful adverse effect known as chemotherapy induced mucositis (CIM) that is 
characterized by inflammation of the mucosal lining within the alimentary tract. Mucosal 
damage associated with CIM is the most common dose limiting side effect of 
chemotherapy.  CIM produces swollen and painful ulcerations within 5 to 14 days post-
administration of the chemotherapeutic agent. The pain induced by CIM can diminish a 
patient’s ability to eat, talk, drink or swallow thus resulting in delayed and often alters 
dosing of chemotherapeutic treatments and compromises appropriate nutrition therapy. 
The signs and symptoms of CIM begin with the onset of vomiting, diarrhea, a decrease in 
caloric intake and weight loss 2.  
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Investigational animal models aid in the development of disease interventions. 
Research on CIM is dominated by investigations conducted on mice, rats or in vitro 
processes. The present research aims to develop a novel porcine animal model for the 
induction of chemotherapy-induced mucositis (CIM). The objectives of this study are to 
determine the timeline and dosing regimen of chemotherapy to induce alimentary tract 
mucositis. Although prior investigations of CIM have been invaluable for the 
advancements made in physiological concepts, a porcine model would be more relevant 
to human CIM and would yield translational data 3-6. The porcine model shares more 
similarities with humans than rodent species with regard to the anatomical, physiological, 
immunological, and metabolic characteristics 7-9. 
Combining an appropriate animal, the pig, with a clinically relevant 
chemotherapeutic agent, in this case Doxorubicin (DOXO), was the basis for the 
development of a novel animal model of CIM 10. A relevant animal model can be utilized 
for the advancement and evaluation of CIM interventions. At this time the interventions 
available for the alleviation of CIM are marginally effective and include oral numbing 
medications, intravenous pain medications, relaxation techniques, and cessation of 
treatment. The availability of a relevant animal model is imperative to the future 
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REVIEW OF LITERATURE 
 Malignant neoplasms are locally invasive with destructive growth and possible 
metastasis. Neoplasms are tissues set apart from adjacent normal tissues by abnormally 
rapid proliferation with continued growth post irregular stimulation. Metastasis involves 
cancer cells and the disease process disseminating from the primary tumor site to 
secondary regions of the body via the lymphatic system, blood vessels, or by direct 
extension via cavities or other spaces. Essentially, cancer involves the progressive 
accumulation of genetic changes that facilitate irregular and rapid proliferation of cells 
with the potential to spread to surrounding tissue via diverse metabolic pathways 11.   
Pediatric Cancers  
In 2010, approximately 10,700 new cases or one percent of all cancer patients 
were represented by children under the age of 20 years old 1,12,13. The most prevalent 
pediatric cancers include Hodgkin and non-Hodgkin lymphoma, Acute Lymphoblastic 
Leukemia (ALL), Acute Myeloid Leukemia (AML), brain tumors, and Wilms’ tumor, a 
childhood solid tumor of the kidneys 1,12-16.  
 Lymphomas cause swollen lymph nodes and have the potential to metastasize to 
the bone marrow and other organs. Leukemias are a progressive proliferation of abnormal 
leukocytes, white blood cells (WBC), typically found in hemopoitetic tissues and in the 
blood. Wilms’ tumor is diagnosed by a lump or swelling of the abdomen. Combined, 
these cancers represent approximately 66% of all childhood cancers 1,11.  
Cancer Progression    
When cancer presents itself, early detection is crucial to the effectiveness of 
cancer interventions 17. Anatomical characteristics in addition to prognostic models 
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determining size, location, and severity allow for early detection to ensure proper 
diagnosis and therefore choice of therapy 1. A multitude of interventions or therapies are 
currently available in various therapeutic regimens. Interventions range from surgical 
resection to chemotherapy and radiotherapy or combination therapy to create a 
synergistic effect.   
Anthracycline Agents for Cancer Chemotherapy 
  One class of chemotherapeutic agents known as anthracyclines, plays a vital role 
in the treatment of many pediatric cancers 15. In the 1960s cultures of Streptomyces 
peucetius were discovered to have cytotoxic antineoplastic properties 18, leading to the 
development of the anthracycline drugs now used in pediatric oncology. More than 50% 
of pediatric cancer survivors have received anthracycline chemotherapeutic agents as a 
part of their cancer treatment regimen.  Anthracycline agents are considered to be a key 
reason why the 5-year survivor rate has increased from approximately 30% in the 1960s 
to approximately 70-80% today 15.  
Doxorubicin (Adriamycin) 
 Doxorubicin (DOXO hereafter) is marketed for intravenous use only. The most 
commonly used dosage of DOXO for pediatric patients is 40 to 60 mg/m2 and is 
administered as a single intravenous injection every 21 to 28 days. Some modifications 
are necessary depending on the current health status of the individual patient 18. 
Variations of co-treatment options differ depending on the type and extent of cancer.  
 The anticancer properties of DOXO are attributed to inhibition of topoisomerase 
II, which is essential for DNA replication and repair by resolving DNA under and over-
winding, knots and tangle complications that exist within genetic material 15,19. DOXO 
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interferes with the performance of topoisomerase II through intercalation, which is an 
insertion of DOXO between the DNA strands. This effectively inhibits proliferation of 
rapidly growing cancer cells by blocking DNA replication 11,15. The result of DOXO 
administration is a blockage of the cell cycle at the G2/M phase.   Basically, by blocking 
DNA replication and the cell cycle (mitosis), DOXO inhibits further replication of cancer 
cells. Moreover, DNA binding to the anthracycline instead of the topoisomerase leads to 
the apoptotic pathway or programmed cell death (PCD) 20. This mechanism is the body’s 
mechanisms of eliminating cells that are not capable of reproducing.  In essence the cell 
dies due to the inhibition of cellular replication, with rapidly proliferating cancer cells 
preferentially affected. 
Gastrointestinal Tract Susceptibility to DOXO 
 Unfortunately, cancer cells are not the only rapidly proliferating cells within the 
body. The gastrointestinal tract (GIT) epithelium, from the mouth to the anus, is a highly 
proliferative system. Cell turnover rates within the GIT are approximately 24 to 48 hours. 
Because of the limited lifespan as well as the limited selectivity of the anthracycline, the 
GIT becomes susceptible to the mechanism of action of the anthracycline antibiotic, 
DOXO 21. In short, DOXO affects proliferation of GIT cells as well as cancer cells. In 
addition to the GIT there are other tissues in which DOXO produces side effects but these 
effects will not be discussed in detail. Due to the impact of DOXO on tissues dependent 
on highly proliferative cells, side effects include mucositis, nausea, vomiting associated 
with the GIT, alopecia (hair loss), and anemia 14.  
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Progression of Mucositis Phases and the Significance of Cytokines  
 Mucositis is the focus of this research and literally means inflammation of the 
mucosal lining of the digestive system. Mucositis develops within 5 to 10 days after onset 
of treatment. It is described as an adverse reaction of the gastrointestinal section in the 
prescribing information of the medication 18. All regions of the alimentary tract from 
mouth to anus are susceptible to mucosal damage caused by DOXO and other 
chemotherapeutic agents. The theory behind the pathophysiology of mucositis is 
activation of nuclear factor KB (NF-KB).  NF-KB promotes the upregulation of key pro-
inflammatory cytokines, such as tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β) 
and interleukin-6 (IL-6). These pro-inflammatory cytokines are considered to play an 
important role in the five phases of mucositis development and progression. These 
include initiation, upregulation and message generation, signal amplification, ulcerative, 
and healing phases 22,23. The initiation phase occurs immediately after exposure to the 
cytotoxic agent and involves direct damage to the mucosal tissue components due to the 
production of reactive oxygen species (ROS). ROS are a by-product of the reactions 
involved with chemotherapy metabolism 24.  The upregulation and message generation 
phase incorporates the activation of the transcription factor NF-KB in response to the 
chemotherapy administration. Once activated, NF-KB signals up to 200 genes that trigger 
clonogenic cell death, apoptosis, and mucosa tissue damage. Additionally, the pro-
inflammatory cytokines, TNF, IL-B, and IL-6, are produced in response to the activation 
of NF-KB 23. The signal amplification phase involves pro-inflammatory cytokines 
triggering additional NF-KB activation and thus more pro-inflammatory cytokines are 
produced in response to the second NF-KB activation. The ulcerative phase occurs as 
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soon as there is a breach in the epithelium, which can be accompanied by bacterial 
colonization. It is only at this stage when tissue damage produced by mucositis is 
clinically evident. Finally, the healing phase is induced after cessation of the 
chemotherapy treatment. Clinical evidence indicates as mucositis resolves, re-
epithelialization takes place 23.  
DOXO and Mucositis: Side Effect and Dose Limitation  
The degree of mucositis, including the incidence and severity, are related to the 
amount and type of chemotherapy administered. Even conventional dosing schedules can 
induce potentially serious complications, such as severe local discomfort, pain, and 
diminished nutrition status, dehydration, debilitating oral pain as a result of ulcerations, 
abdominal bloating, vomiting, and diarrhea. These side effects can delay subsequent 
chemotherapy and lead to dose reductions if there is no resolution of the mucositis 23. 
Inevitably, this reduces chemotherapy efficacy and can decrease in the survival rate of the 
cancer patient population due to the provision of altered treatment below therapeutic 
standards 25. Therefore, mucositis is classified as one of the major dose limiting factors of 
chemotherapy. If mucositis were to be alleviated or even prevented from occurring in 
patients undergoing chemotherapy, the degree of suffering would be lessened, and dosage 
could be increased 25. 
Mucositis Treatment Options  
Current clinical treatments for patients diagnosed with mucositis are limited to 
oral analgesics and intravenous pain medications.  Growth factors, cytokines, receptor 
agonists/antagonists, and anti-inflammatory agents are being explored as treatment 
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options 26.  A limiting factor in the development and evaluation of interventions for 
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CHAPTER II 
MATERIALS AND METHODS  
Pigs and their Care 
The University of Memphis Institutional Animal Care and Use Committee had 
approved all aspects of the research involving animals (UM IACUC protocol #0672).  A 
total of 12 weaned farm pigs approximately 28 days old ± 4 days were obtained from a 
commercial specific pathogen free supplier. The pigs were housed in Polydome Litter 
Saver Pig Nurseries divided into two sections with final dimensions of 61cm by 76cm, 
with environmental enrichment provided, and located in a room maintained at 22 C (+ 1° 
C).  The pigs were housed individually and fed Prime Quality Pig Starter (Cargill 
Incorporated Minneapolis, MN) three times each day at 150 g per feeding. The pigs were 
allowed access to the food for 15 minutes after which the remaining food was weighed 
for estimating daily consumption.  The intensity of feeding was also recorded as a 
subjective indicator.  Water was continuously available.  The pigs were weighed and had 
daily frequent human interactions to facilitate chemotherapy administration and handling 
27,28.  
Surgical Catheterization 
Catheters (3.5 French Umbilical Artery Catheters) were surgically placed in the 
right carotid artery and exteriorized on the dorsal surface at the base of the neck for 
collection of blood and for administration of the chemotherapeutic agent, Doxorubicin, 
HCL (DOXO; Bedford Laboratories, Bedford, OH).  The surgery was performed 3 days 
after the pigs were obtained, allowing the pigs to acclimate to the new environment and 
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feeding regimen.  The pigs were fasted overnight before the surgery.   The pigs were 
sedated with Telazole (10 mg/kg), anesthesia was maintained using Isoflurane (2% with 
oxygen), and a sterile surgical field was prepared.  Carprofen (4 mg/kg) was used post 
surgery for analgesia and Baytril (5-10 mg/kg) was administered prophylactially to 
prevent infection. The catheters were flushed 2-3 times daily with heparinized saline (100 
units/ml).   
Administration of Doxorubicin 
The pigs were allowed to recover for a minimum of two days after surgery or 
until pre-surgery feeding intensity was regained before administration of DOXO.   The 
doses (Table 1) were calculated for each pig as the appropriate Human Equivalent Dose 
(HED)/Animal Dose (AD) 29-30. A preliminary pig was administered 6.25 mg/kg (125 
mg/m2; n=1).  This dose exceeds by roughly 2-fold the maximum dose that would be 
provided to a child.  The intention was to determine if DOXO would induce GI 
dysfunctions as in humans.  The remaining pigs were administered DOXO at 5 mg/kg 
(100 mg/m2; n=4) and the clinically relevant dose of 3.75 mg/kg (75 mg/m2; n=4).  The 
dosages were provided via the catheter over a 30 min period by administering 1/6th of the 
dosage every 5 minutes per pig.  Control pigs (n=3) received the same volume of saline 
using the same dosing regimen.  The feeding regimen was maintained after 
administration of DOXO. 
An additional two of the pigs dosed with 75 mg/m2 DOXO were provided bovine 
colostrum at 5 ml/kg body weight 3x/d beginning the day before and continuing after 
administering the dose of DOXO.  This was to evaluate if colostrum would alleviate the 
adverse impact of DOXO on gastrointestinal structure and functions. 
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Table 1. Doxorubicin dosages used to induce mucositis in weaned pigs.  
Group 
Human Equivalent Dose 
(HED) 
Animal Dose        
(AD) 
n 
1 125mg/m2 6.25mg/kg 1 
2 100 mg/m2 5mg/kg 4 
3 75 mg/m2 3.75mg/kg 4 
4 0; Lactated Ringers 2 ml/kg 3 
 
Data Collection 
Food consumption (intensity of feeding and amount eaten) was recorded daily 
before and after administration of DOXO.  After DOXO was administered each pig was 
observed a minimum of 3 times daily and general health status, vomiting frequency, stool 
consistency (assessed according to Table 2) and body weight were reported 35. 
 
Table 2. Diarrhea Assessment Chart  
Stool Score Stool Grade/ Consistency Description 
0 Normal Stool Normal or Absent Stool 
1 Slight Diarrhea Slightly Wet and Soft Stool 
2 Moderate Diarrhea 
Wet and Unformed Stool 
Moderate Coat Staining Around the Anus 
3 Severe Diarrhea 
Watery Stool 
Severe Coat Staining Around the Anus 
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Cytokines 
Blood samples were collected in EDTA tubes immediately prior to the 
administration of DOXO, every morning thereafter, and immediately prior to euthanasia.  
Blood samples were centrifuged and aliquots of the plasma were frozen (-70° C) until 
used to measure concentrations of inflammatory (IL-6, TNF-α) and anti-inflammatory 
(IL-10) cytokines by enzyme-linked immunosorbent assays (ELISA; R&D Systems, 
Minneapolis, MN) following the manufacturer's instructions. 
Necropsy and Tissue Collection 
After euthanasia (Beuthanasia, Schering-Plough Animal Health Corp., Union, NJ, 
1ml/kg; IV) the mouth was examined for lesions.  The entire gastrointestinal tract was 
exposed and externally visible lesions were recorded.  A 1-2 cm segment of esophagus 
immediately distal to the pharynx was removed and placed in neutral buffered formalin.  
The stomach was opened, the interior was observed and a 1-2 cm2 full thickness patch 
from the greater curvature was fixed in formalin.  The small intestine was removed, the 
associated mesenteries cut, and length measured from the pyloric sphincter to the 
ileocolonic junction.  Intact segments of 15-20 cm were removed from the proximal, mid 
and distal thirds of the small intestine (Figure 1).  From each of these regions a 1-2 cm 
segment was fixed in formalin, another 5-7 cm was flash frozen in liquid nitrogen and 
stored at -70° C, and the remainder of the segment was placed in chilled (2-4° C) 
mammalian Ringers and transferred to the lab for in vitro studies (data not presented).  
Segments of 1-2 cm were removed from the proximal, mid, and distal colon and fixed in 
formalin.   
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Histology  
The tissues were processed by Integrated Microscopy Center at the University of 
Memphis.  Briefly, the full thickness, formalin fixed tissues were dehydrated, embedded 
in paraffin and 5 µm sections were stained with Lillie–Mayer’s haematoxylin and 
counterstained with eosin.  Histopathology observations were performed on a light 
microscope with an optical micrometer.   
 The overall severity of mucositis in the jejunum and proximal colon was scored 
based on a semi-quantitative histological assessment of intestinal damage 31. Each region 
was assessed and given a summative value based on the following scores, 0 (normal) to 3 
(maximal damage). The maximum possible score, 21, was based on the following 
inclusion criteria, villus fusion and stunting (atrophy), disruption of brush border and 
surface enterocytes, reduction in goblet cell number, crypt loss/architectural disruption or 
distortion of crypt cells, infiltration of polymorphonuclear cells and lymphocytes, in 
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Figure 1. Histology sample site 
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CHAPTER III 
RESULTS  
Food Consumption, Body Weight Gain, and General Health 
Control pigs continued to eat the ration aggressively, gained body weight, 
responded to enrichment and human interactions, and remained healthy based on stool 
scores and lack of vomiting or any evidence of GI dysfunctions (Figures 2-5; Tables 3-6).  
Administration of DOXO at all doses elicited rapids declines in food consumption 
and weight loss (Figures 2-3; Tables 3-4).  Within 24 h after DOXO administration the 
pigs lost interest in enrichment and human interactions and became lethargic.  Vomiting 
was first seen 24 h after the dosage and became severe on day 3 (Figure 4; Table 5).  By 
this time food consumption fell below 20% of pre-administration intake.  Vomiting 
declined thereafter and was not seen the day of necropsy.  Stool consistency declined 
rapidly after DOXO administration, and particularly after day 2.  Profuse watery diarrhea 
was evident until necropsy (Figure 5; Table 6). All pigs receiving DOXO exhibited signs 
of wasting at day 4-5, based on continued weight loss and the prominence of bony 
processes associated with the pelvis, scapula, and spine, with reduced abdominal adipose 
tissue and muscle tone.  At the time of necropsy, pigs dosed with DOXO had lost 5-20% 
of body mass compared with the start of chemotherapy 27.   
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Figure 2. Comparison of food consumption between Control and Doxorubicin group 1 
day before and after administration of 75mg/m2 until necropsy. Values are expressed as 
percentages of pre-administration values. 
 
Table 3. Comparison of food consumption between Control and Doxorubicin group 1 day 
before and after administration of 75mg/m2 until necropsy. Values are expressed as 
percentages of pre-administration values. 
Daily Food Consumption 
Average Daily Intake Doxorubicin Control 
Day -1 93.20% 51.77% 
Day 0 65.5% 68.97% 
Day 1 58.4% 60.23% 
Day 2 45.7% 67.57% 
Day 3 19% 59.87% 
Day 4 7.37% 82% 
Day 5 10% 92.7% 
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Figure 3. Comparison of body weight change between Control and Doxorubicin group 1 
day before and after administration of 75mg/m2 until necropsy. Values are expressed as 
percentages of pre-administration values. 
 
Table 4. Comparison of body weight change between Control and Doxorubicin group 1 
day before and after administration of 75mg/m2 until necropsy. Values are expressed as 
percentages of pre-administration values. 
Weight Change 
Average Daily Intake Doxorubicin Control 
Day -1 +10.9% +7.53% 
Day 0 +6.66% +7.31% 
Day 1   
Day 2   
Day 3   
Day 4   
Day 5 -17.16% +16.89% 
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Figure 4. Changes in vomiting between Control and Doxorubicin group 1 day before and 
after administration of 75 mg/m2 of Doxorubicin until necropsy.  Values are expressed as 
percentages of pre-administration values. 
 
Table 5. Changes in vomiting between Control and Doxorubicin group 1 day before and 
after administration of 75 mg/m2 of Doxorubicin until necropsy.  Values are expressed as 
percentages of pre-administration values. 
Vomiting 
Average Daily Intake Doxorubicin Control 
Day -1 0% 0.0% 
Day 0 0% 0.0% 
Day 1 0% 0.0% 
Day 2 5.6% 0.0% 
Day 3 50.0% 0.0% 
Day 4 22.2% 0.0% 
Day 5 0.0% 0.0% 
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Figure 5. Incidence of diarrhea between Control and Doxorubicin group 1 day before and 
after administration of 75 mg/m2  of Doxorubicin until necropsy.  Values are expressed as 
percentages of pre-administration values. 
 
Table 6. Incidence of diarrhea between Control and Doxorubicin group 1 day before and 
after administration of 75 mg/m2 of Doxorubicin until necropsy.  Values are expressed as 
percentages of pre-administration values. 
Diarrhea 
Average Daily Intake Doxorubicin Control 
Day -1 0.0% 0% 
Day 0 3.7% 0% 
Day 1 3.7% 0% 
Day 2 11.1% 0.0% 
Day 3 74.1% 0.0% 
Day 4 100.0% 0.0% 
Day 5 100.0% 0.0% 
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Cytokine Data  
 
Figure 6. TNF-α cytokine concentrations. Values are expressed in pg/ml. Day 0 indicates 
the initial sample prior to chemotherapy with all days leading to necropsy on day 5.  
 
 
Figure 7. IL-6 concentrations. Values are expressed in pg/ml. Day 0 indicates the initial 
sample prior to chemotherapy with all days leading to necropsy on day 5. 
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Figure 8. IL-10 concentrations. Values are expressed in pg/ml. Day 0 indicates the initial 
sample prior to chemotherapy with all days leading to necropsy on day 5. 
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Histopathology  
The jejunum and proximal colon of pigs receiving DOXO had disrupted 
morphology and structural integrity (Figure 9).  This was evident at all doses, including 
(75mg/m2).  Microscopic examination of control pigs (Figure 9) did not reveal evidence 
of epithelial hyperplasia, structural or cellular alterations, or significant histological 
changes.  
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Figure 9. Control jejunum (A) and proximal colon (C). Doxorubicin administration 
(75mg/m2): Severe jejunal villous atrophy and blunting (B) and diminished proximal 
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CHAPTER IV 
DISCUSSION 
 Chemotherapy alone or in conjunction with surgery or radiation remains the 
cornerstone of cancer therapy and has contributed to the rise in pediatric cancer survival 
rates 32. Anthracyclines (DOXO) are a recognized class of chemotherapy known to have 
contributed to the steady improvements in prevailing over pediatric cancers 33, 34. 
However, future research is required to develop safe and effective interventions for the 
debilitating and potentially dose limiting factors associated with the side effects of 
chemotherapies.  
 The dose limiting factor, mucositis, afflicts approximately 40% of patients 
receiving standard dose and 100% of patients receiving high dose chemotherapy 35,36. 
Agents such as DOXO, are known to amplify these mucotoxic findings 37,38.  Although 
scientific advancements have improved pediatric cancer survival rates, occurrence of 
mucositis decreases quality of life, increases treatment interruptions or even delays 
therapy, and often reduces the dose 23,32,39.  
General Health and Clinical Symptoms  
 Mucositis in response to chemotherapy is defined by inflammatory lesions of the 
mucosal lining of the oral and/or gastrointestinal tract as a result of standard or high-dose 
cancer therapy 40,41. This study demonstrated mucositis develops similarly in weaned pigs 
after administration of DOXO at 75 mg/m2, 100 mg/m2, and 125 mg/m2.   At 75 mg/m2, 
which is a clinically relevant dose, mucositis characteristics were comparable to those 
described for pediatric cancer patients receiving chemotherapy. Although the pigs did not 
	   25 
vocalize discomfort, the symptoms of mucositis were evident based on the declines in 
food consumption and weight gain, the increased frequency of vomiting, and diarrhea, 
and lethargic behavior.  These responses are consistent with literature reports pertaining 
to pediatric oncology and chemotherapy.  
A multitude of factors influence chemotherapy-induced nausea and vomiting 
(CINV). Pediatric patients are especially at higher risk for emesis solely based on age. 
There are varying theories indicating chemotherapy’s interference/influence on the vagus 
nerve, which activates the dorsal vagal complex 42. This is considered to be the primary 
mechanism by which most chemotherapeutic agents initiate acute emesis.   Emetogenic 
levels of intravenously administered antineoplastic agents have been classified into four 
divisions (high, moderate, low, and minimal) and these have been the standard for 
defining emetogenicity. DOXO was categorized as moderate, with 31% to 90% of 
patients anticipated to develop vomiting 42-44.  
 After onset of CINV, food consumption declines and is followed by cancer 
cachexia, which affects almost two thirds of cancer patients and increases morbidity and 
mortality 45,46.  Cancer cachexia is mulitfactoral and causes an energy imbalance with a 
progressive loss of lean and adipose tissue attributed to decreased dietary intake as a 
result of a variety of metabolic alteration including anorexia, dysphagia, dysgeusia, pain 
or fatigue 47,48. Cancer combined with the chemotherapeutic regimen compromises 
physical and mental status, including eating behavior. Limiting food intake partially 
alleviates the discomforts caused by cancer, but in doing so exacerbates the weight loss 
increasing morbidity and increasing mortality 49. Our study clearly indicated a decline in 
food consumption and weight gain post DOXO administration. 
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Chemotherapy induced diarrhea (CID) further contributes to the weight loss. A 
serious potentially life-threatening side effect, CID is one of the most evident pathologies 
associated with CIM 50-52. Various analyses suggest the pathophysiology of CID is caused 
by the initial cytotoxic insult to the crypt cells of the intestinal epithelium.  Diminished 
digestive ability has been attributed to decreased enzyme secretory capacity, enzyme 
imbalances, and altered osmotic gradients that collectively enhance the progression of 
nutrition malabsorption and fluid and electrolyte losses 53.  
Circulating Cytokines 
The lack of changes in the measured cytokines conflicts with reports for a 
decrease in the anti-inflammatory cytokine, IL-10, and increases in pro-inflammatory 
cytokines, IL-6 and TNF-α, after patients receive chemotherapy 23,41,54-57.  However, this 
study necropsied pigs 5-6 days after administration of chemotherapy.  This is earlier than 
when inflammatory cytokines are reported to increase in human subjects receiving 
chemotherapy.  Based on conversations with our oncology colleagues at St Jude 
Children’s Research Hospital, providing parenteral nutrition after the pigs cease to eat 
and thereby extending the post administration period and increasing the severity of 
mucositis would likely elicit the previously reported changes in circulating cytokines. 
Additionally, previous reports indicate cytokines increase in response to stress factors 58-
61.  For the present study, several uncontrollable variables, including transport to the 
animal facilities, solitary housing, dietary change, and surgical placement of the catheter 
could have caused an elevation in the cytokine baseline.  If so, this could have obscured 
post-administration responses and differences between the control and treatment groups.    
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Gross Anatomy and Histopathology 
Observations at necropsy revealed lesions in the mouth and throughout the 
gastrointestinal tract of pigs treated with DOXO, but not control pigs. Histological 
microscopic observations coincided with findings reported by other researchers 62,63. Our 
findings included observations of severe morphological and architectural damage.  
Specifically, severe villus atrophy, crypt loss, disturbance of crypt arrangement, 
flattening of crypt and villus epithelium, and mucosa and submucosa thickening. 
Collectively, these findings confirm the diagnosis of mucositis.  
Pig Versus Rodent Model 
Oncology research currently has various investigational models for examining 
oral and gastrointestinal mucositis, ranging from in vitro systems to rodents 37,62,64-66.  
Discrepancies about interspecies comparisons emerge from the literature based on the 
functional differentiation of the GIT that begins during embryological development.  It 
has been argued that dissimilarities of the GIT will not impact the specific mechanisms of 
gastrointestinal mucositis 67.  Within the same debate, the evidence provided to confirm 
the similar mechanisms of chemotherapy-induced mucositis is limited. Future animal 
model development requires examination of two areas. One is the relevance of the 
animal, and the second is the responses of the entire gastrointestinal tract (GIT) to 
eradicate gaps in information and either confirm or deny prior mucositis theories. The 
porcine model developed herein shares more similarities with humans than most other 
non-primate species with regard to the anatomical, physiological, immunological, and 
metabolic environment of the GIT 7-9. A recent review stated, “Few consistent animal 
models exist that investigate mucositis in the remainder of the gastrointestinal tract  
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(GIT) 37.” These statements confirm the necessity for the development of a novel porcine 
model for chemotherapy-induced mucositis.  
Conclusion 
This study developed a porcine model for chemotherapy-induced mucositis. 
Administration of DOXO at a clinically relevant dose of 75mg/m2 induces mucositis 
within 4 to 5 days post-administration. Severe morphological damage to the alimentary 
tract mucosa is accompanied by declines in food consumption and weight gain, increased 
frequency of vomiting, diarrhea, and lethargic behavior.  Previous discussion leads to the 
conclusion the weaned pig is a relevant model in which the entire GIT can be examined. 
At the forefront of cancer research is the necessity for interventions that alleviate or 
eliminate CIM. A better understanding of the mechanisms of mucositis will facilitate this 
effort.  Various agents are available for rescue post-chemotherapy administration. What if 
there was a mucositis intervention available for administration with chemotherapy in 
order to prevent this adverse side effect? Together with the collaboration of a team of 
oncological experts, the porcine model has the potential for testing interventions to 
eliminate the dose-limiting factor of CIM. Of particular interest is colostrum. The GIT is 
well known to provide barrier protection and immunity. Chemotherapy introduces a 
breach in this protective function. Colostrum is well known to have immunological 
properties and may have great applications for patients receiving chemotherapy that 
induces mucositis. Future directions for this project include a preliminary study that 
evaluated colostrum as a potential intervention.  This effort is currently in progress.  
Colostrum has the potential to reduce the severity of mucositis, but the bioactive fractions 
and mechanisms of action are unknown.  
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